Skip to main content

Main menu

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • JABFM on Bluesky
  • JABFM On Facebook
  • JABFM On Twitter
  • JABFM On YouTube
Research ArticleSpecial Communications

Hepatitis C Update and Expanding the Role of Primary Care

Gina M. Simoncini and David E. Koren
The Journal of the American Board of Family Medicine May 2019, 32 (3) 428-430; DOI: https://doi.org/10.3122/jabfm.2019.03.180286
Gina M. Simoncini
From Lewis Katz School of Medicine at Temple University, Philadelphia, PA (GMS); Temple University Hospital, Philadelphia, PA (DEK).
MD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David E. Koren
From Lewis Katz School of Medicine at Temple University, Philadelphia, PA (GMS); Temple University Hospital, Philadelphia, PA (DEK).
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Abstract

Primary care physicians (PCPs) are increasing their role in the fight against the Hepatitis C Virus (HCV). Approximately 3.5 million Americans currently live with chronic HCV with rising incidence among young persons, especially those affected by the opioid epidemic. Online guidelines and drug interaction checkers streamline treatment and increase accessibility for both patients and providers. Although treatment with new Direct Acting Antiviral agents ensure cure rates that routinely exceed 95%, as well as cause fewer adverse effects than previously available interferon-based regimens, some states still restrict access to HCV treatment, including by mandating which providers can prescribe and treat HCV. This special communication reviews HCV treatment resources, discusses data demonstrating similar cure rates between PCPs and specialists, and argues that capacity-building among PCPs will be necessary to control the HCV epidemic.

  • Antiviral Agents
  • Hepatitis C
  • Primary Care Physicians
  • Sustained Virologic Response

According to the Centers for Disease Control and Prevention, there are over 3.5 million Americans living with hepatitis C virus (HCV).1 Persons born between 1945 and 1965 comprise the majority of Americans living with HCV; however, HCV incidence has been rising among young persons, especially those affected by the opioid epidemic.1,2 Treatment for HCV, now using direct-acting antivirals (DAAs), made staggering progress in the past 6 years with sustained virologic response rates that now routinely exceed 95%. These new regimens are both simpler to administer and have fewer adverse effects than previously used interferon and ribavirin-based regimens. Therefore, we believe this is an opportune time for primary care physicians (PCPs) to become familiar with the DAAs. In addition, the first generic options for treatment have now been released, which will hopefully expand access to care.

Several DAA combination products are available in the United States. A general comparison of the four first-line recommended regimens used in treatment-naïve patients can be found in Table 1. Individual DAA agents fall into 3 distinct classes: nonstructural (NS) protein inhibitors 3/4 affecting viral protease, NS5b affecting RNA polymerase, and NS5a with an unknown mechanism of action. The combined American Association for the Study of Liver Diseases/Infectious Diseases Society of America maintain an online guideline for the management and treatment of hepatitis C, found at www.hcvguidelines.org.3 These guidelines provide further prescribing information, including management of patients with cirrhosis or with comorbidities such as HIV or chronic kidney disease.

View this table:
  • View inline
  • View popup
Table 1.

Comparison of Recommended First-Line Direct-Acting Antiviral Regimens Used for Treatment of Treatment-Naïve Hepatitis C Patients, as of 1/1/2018

The most common drug-drug interactions involve these agents and β-hydroxy β-methylglutaryl-coenzyme A reductase inhibitors (statins), acid-suppressing medications, and antiepileptics. However, for clinicians managing potential and known interactions, the University of Liverpool comprehensive drug interaction database, found at www.hep-druginteractions.org, remains the most complete tool.4 In practice, side effect profiles of the DAA agents remain minimal, with adverse effects such as headache, nausea, and fatigue as the most common symptoms throughout clinical trials.

Although these medications are safe and effective, some states still have restrictions about HCV treatment. Some states have fibrosis and/or sobriety restrictions that restrict treatment based on a patient's degree of liver damage or sobriety length. In addition, some states restrict the scope of practice of PCPs by requiring a specialist or a PCP in coordination with a specialist to treat patients living with HCV. A summary list of these restrictions by state can be found at stateofhepc.org. Despite these restrictions, there are studies that demonstrate that trained PCPs can not only treat HCV but also have similar outcomes as specialists. In 2004, Project Extension for Community Health care Outcomes (ECHO) began using case-based learning and videoconferencing with specialists to train PCPs to independently deliver HCV treatment in New Mexico.5 Before the training, none of the PCPs had treated HCV. During the published study period (2004 to 2008), Project ECHO enrolled 261 patients who were treated by PCPs and 146 patients who were treated by specialists using interferon-based therapy. Sustained virologic response rates were similar across both groups (PCPs, 45.8% and specialists, 49.7% [P = .57)]). Most recently, A Phase IV Pilot Study to Assess Community-Based Treatment Efficacy in Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia (ASCEND) group demonstrated that PCPs, including nurse practitioners, were capable of providing effective DAA HCV therapy after a 3-hour training.6 Cure rates (83% to 89%) among the 600 studied participants did not differ based on provider type, regardless if they were treated by PCPs, nurse practitioners, or specialists, although the cure rates were affected by patient loss to follow up. Both Project ECHO and the ASCEND study built capacity among PCPs to expand access to HCV treatment and demonstrated that high sustained virologic responses are both achievable and consistent among all clinician types.

Primary care providers seeking to treat hepatitis C should be aware that all insurance companies currently require prior authorization for payment on a DAA. Both virus-specific, such as HCV genotype, and comorbidity-specific labs, such as HIV and hepatitis B status, are required to be submitted with the authorization. Specific documentation of any adherence barriers, including mental health and sobriety, may need to be addressed by the prescriber. Some states also require prescribers to counsel patients on sobriety from drugs and alcohol. It is recommended that providers research their patients' commonly used insurance plans to both meet these requirements, as well as determine the preferred formulary agent on a patient's plan because there are high rates of insurance denials of HCV treatment. A study of national HCV DAA prescription trends demonstrated that 35% of patients were denied HCV treatment by insurance. Commercial insurance plans denied 52.4% of prescriptions submitted, Medicaid denied 34.5%, and Medicare denied 14.7% of HCV DAA prior authoritizations.7 These denials from insurance do create an administrative burden for providers who treat HCV, and as such, we recommend a multidisciplinary approach, including pharmacy representatives, to enhance the transparency of insurance coverage and assist with medication accession.

The National Viral Hepatitis Roundtable and the Center for Health Law and Policy Innovation of Harvard Law School published a report demonstrating 35 state Medicaid programs requiring a specialist to either consult or directly prescribe DAA therapy.8 These restrictions effectively limit access to HCV treatment. We agree with the American Academy of Family Physicians and the expert committee convened by the National Academy of Sciences that PCPs who have the desire and medical knowledge should be permitted to treat and prescribe DAAs for HCV.9,10 State-level advocacy to change Medicaid provider restrictions, while simultaneously training PCPs to build capacity to treat HCV, will be the necessary next steps to control the HCV epidemic and reach patients in areas that often lack specialist care, especially in rural areas.

Notes

  • This article was externally peer reviewed.

  • Funding: none.

  • Conflict of interest: Gilead Sciences, Inc. (research funding - GMS, DEK, advisory board - DEK) and ViiV Healthcare (advisory board - DEK).

  • To see this article online, please go to: http://jabfm.org/content/32/3/428.full.

  • Received for publication September 24, 2018.
  • Revision received January 4, 2019.
  • Accepted for publication January 8, 2019.

References

  1. 1.↵
    Centers for Disease Control and Prevention. Hepatitis C kills more americans than any other infectious disease. Available from: https://www.cdc.gov/media/releases/2016/p0504-hepc-mortality.html. Published 2016. Accessed January 2, 2018.
  2. 2.↵
    Centers for Disease Control and Prevention. New hepatitis C infections nearly tripled over five years. Available from: https://www.cdc.gov/nchhstp/newsroom/2017/Hepatitis-Surveillance-Press-Release.html. Published 2017. Accessed January 2, 2018.
  3. 3.↵
    American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available from: http://www.hcvguidelines.org. Published 2014. Accessed January 5, 2018.
  4. 4.↵
    University of Liverpool. Hep drug interactions. Available from: https://www.hep-druginteractions.org/checker. Published 2019. Accessed January 8, 2018.
  5. 5.↵
    1. Arora S,
    2. Thornton K,
    3. Murata G,
    4. et al
    . Outcomes of treatment for hepatitis c infection by primary care providers. N Engl J Med. 2011;364:2199–220707.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Kattakuzhy S,
    2. Gross C,
    3. Emmanuel B,
    4. et al
    . Expansion of treatment for hepatitis c virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial. Ann Intern Med 2017;167:311–8.
    OpenUrl
  7. 7.↵
    1. Gowda C,
    2. Lott S,
    3. Grigorian M,
    4. et al
    . absolute insurer denial of direct-acting antiviral therapy for hepatitis C: a national specialty pharmacy cohort study. Open Forum Infect Dis. 2018;5:ofy076.
    OpenUrl
  8. 8.↵
    National Viral Hepatitis RoundTable and Center for Health Law and Policy Innovation at Harvard Law School. Hepatitis C: state of medicaid access, provider restrictions. Available from: https://stateofhepc.org/wp-content/uploads/2017/10/Prescriber-Infographic.pdf. Published 2017. Accessed January 2, 2018.
  9. 9.↵
    1. Sederstrom J
    . Prescriber restrictions hurt hepatitis C patients, AAFP argues. Available from: https://www.aafp.org/news/health-of-the-public/20160420hepcaccess.html. Published 2016. Accessed February 7, 2018.
  10. 10.↵
    National Academy of Sciences. A national strategy for the elimination of hepatitis B and C. Available from: http://www.nationalacademies.org/hmd/reports/2017/national-strategy-for-the-elimination-of-hepatitis-b-and-c.aspx. Published 2017. Accessed January 2, 2018.
PreviousNext
Back to top

In this issue

The Journal of the American Board of Family     Medicine: 32 (3)
The Journal of the American Board of Family Medicine
Vol. 32, Issue 3
May-June 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hepatitis C Update and Expanding the Role of Primary Care
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
5 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Hepatitis C Update and Expanding the Role of Primary Care
Gina M. Simoncini, David E. Koren
The Journal of the American Board of Family Medicine May 2019, 32 (3) 428-430; DOI: 10.3122/jabfm.2019.03.180286

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Hepatitis C Update and Expanding the Role of Primary Care
Gina M. Simoncini, David E. Koren
The Journal of the American Board of Family Medicine May 2019, 32 (3) 428-430; DOI: 10.3122/jabfm.2019.03.180286
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
    • References
  • Figures & Data
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Family Medicine: Data Driven Practice with Emphasis on Underserved Patients
  • Google Scholar

More in this TOC Section

  • Integrating Community and Clinical Data to Assess Patient Risks with A Population Health Assessment Engine (PHATE)
  • Primary Care Is an Essential Ingredient to a Successful Population Health Improvement Strategy
Show more Special Communications

Similar Articles

Keywords

  • Antiviral Agents
  • Hepatitis C
  • Primary Care Physicians
  • Sustained Virologic Response

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us
  • ABFM News

© 2025 American Board of Family Medicine

Powered by HighWire